Camurus AB (CAMX)

Currency in SEK
528.00
-8.00(-1.49%)
Real-time Data·
CAMX is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
526.50540.00
52 wk Range
430.80754.50
Key Statistics
Prev. Close
536
Open
539.5
Day's Range
526.5-540
52 wk Range
430.8-754.5
Volume
24.66K
Average Volume (3m)
121.4K
1-Year Change
-0.0946%
Book Value / Share
74.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CAMX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
770.13
Upside
+45.86%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Camurus AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 770.13
(+45.86% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Camurus AB Earnings Call Summary for Q1/2026

  • Q1 2026 revenue fell 5% YoY to SEK 533M due to FX headwinds; stock dropped 8.07% to SEK 501 post-earnings despite 32% operating margin
  • EPS reached SEK 2.42 while operating expenses rose 13% YoY to SEK 328M; R&D spending increased SEK 7M to SEK 138M
  • Sequential revenue grew 15% driven by U.K. distribution model changes; company maintains strong cash position for strategic investments
  • Anticipates significant R&D and U.S. launch costs in H2 2026; planning Oclaiz U.S. launch in Q3 2026 to drive future growth
  • Management confident in pipeline development and strategic investments despite near-term FX volatility and regulatory challenges in key markets
Last Updated: 12/05/2026, 14:34
Read Full Transcript

Earnings

Latest Release
12/05/2026
EPS / Forecast
2.40 / 3.54
Revenue / Forecast
533M / 642.77M
EPS Revisions
Last 90 days

Compare CAMX to Peers and Sector

Metrics to compare
CAMX
Peers
Sector
Relationship
P/E Ratio
46.9x40.4x−0.5x
PEG Ratio
1.97−0.150.00
Price/Book
7.2x3.4x2.6x
Price / LTM Sales
14.3x3.9x3.1x
Upside (Analyst Target)
42.7%131.8%54.0%
Fair Value Upside
Unlock6.7%6.5%Unlock

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; NewBridge Pharmaceuticals; and Eli Lilly for the development of long-acting incretin medicines based on FluidCrystal technology. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Employees
274
Market
Sweden

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
9.32M15.60%4.81B
Other Institutional Investors
33.14M55.46%17.10B
Public Companies & Retail Investors
17.29M28.93%8.92B
Total
59.75M100.00%30.83B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Sandberg Development AB30.60%18,280,6929,798,451
JPMorgan Chase & Co.5.00%2,985,1901,600,062

People Also Watch

96.85
HEM
+0.52%
72.10
VETO
+0.14%
258.60
BONEX
0.00%
149.40
ALIFb
-0.40%
1,725.0
6417
-1.43%

FAQ

What Is the Camurus AB (Stockholm: CAMX) Share Price Today?

The Camurus AB stock price today is 528.00 SEK.

What Stock Exchange Does Camurus AB (CAMX) Trade On?

Camurus AB is listed and trades on the Stockholm Stock Exchange.

What Is the Ticker (Stock Symbol) for Camurus AB?

The stock symbol (also called a 'ticker') for Camurus AB is "CAMX."

What Is the Current Camurus AB Market Capitalisation?

As of today, Camurus AB (Stockholm: CAMX) market cap is 31.61B SEK.

What Is Camurus AB's (CAMX) Earnings Per Share (TTM)?

The Camurus AB EPS is currently 11.35 (Trailing Twelve Months).

When Is the Next Camurus AB Earnings Date?

Camurus AB's next earnings report will be released on 15/07/2026.

Is CAMX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Camurus AB moving averages and other technical indicators, the daily buy/sell signal for CAMX stock is Neutral.

How Many Times Has Camurus AB Stock Split?

Camurus AB has split 1 times. (See the CAMX stock split history page for full effective split date and price information.)

How Many Employees Does Camurus AB Have?

Camurus AB has 274 employees, based on their latest Companies House report.

What is the current trading status of Camurus AB (Stockholm: CAMX)?

As of 21/05/2026, Camurus AB (CAMX) is trading at a share price of 528.00 SEK, with a previous close of 536.00 SEK. The stock has fluctuated within a day range of 526.50 SEK to 540.00 SEK, while its 52-week range spans from 430.80 SEK to 754.50 SEK.

What Is Camurus AB (CAMX) Price Target According to Analysts?

The average 12-month price target for Camurus AB is 770.13 SEK, with a high estimate of 914 SEK and a low estimate of 620 SEK. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +45.86% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.